 |
Pricing
Defining Value in the Post-Turing Landscape
The takeaway from the latest public outcry over drug prices is this: the old way of thinking no longer works. To navigate the rough waters ahead and address public sentiment around the way products are priced, we must both understand the environment and have a clear vision of what needs to change, writes Meg Alexander
...Read more |
 |
Social Media
Tweets & Drugs & Rock n’ Roll: The Power of the Shkreli Shockwaves
Peter Houston was surprised to find himself discussing Turing Pharmaceutical’s Daraprim in the offices of ClassicRock magazine last week. What’s even more surprising was impact the price hike on the toxoplasmosis treatment was having on a punk record label
...Read more |
 |
Global
A Good Patient Advocacy Strategy for Russia
Though advocacy communications is now a recognized part of a company’s access plan in established markets, there no clear-cut path to success in creating an advocacy strategy. In regions such as Russia and CIS, advocacy strategies become even more complex due to the political, cultural and regulatory differences. Nick Hicks looks at ways of overcoming the challenges
...Read more |
PDMA regulations require sample inventory counts to be conducted on a regular basis with all sales representatives. While traditionally documented on paper (and later input into a computer system), technological advances have allowed this information to be captured electronically at the inventory site, providing many benefits to pharmaceutical companies.
 Learn more about the benefits. |
Event
Prix Galien to Highlight Industry Positives
The Prix Galien forum and awards will once again convene some of the industry’s biggest personalities for a day of accolades and introspection on October 27th. In a season full of negativity and criticism, the industry will pause to honor some of its top achievements before bracing itself for a combative political year. Casey McDonald previews this year’s event
...Read more |
Ready to shed new light on your brand launch success? Introducing Zephyr Illuminate™, the only insights-as-a-service solution for precise and confident decision-making across your entire product lifecycle. You can uncover up to 25% new high potential targets, increase revenue from new and existing customers, and optimize your team's activities and sales channels. Zephyr Illuminate mobile helps align home office and field on marketing strategies and campaigns, maximizing productivity.
 Read more |
From Pharm Exec Magazine
Pharm Exec's 14th Annual Industry Audit
If it was any other year, Pharm Exec’s 2014 Industry Audit results would be considered as a standout performance. But coming just on the heels of the industry’s spectacular revenue run up in 2013-2012, it dims a bit in comparison. But in a global business environment marked by collaborative, cross-sector relationships, it shows that biopharmaceuticals continue to lead other industries by outpacing the overall growth in the US economy
...Read more |
Pharmaceutical Executive E-Book – Coming November 2015: Securing the Global Supply Chain: Strategies for Operational Excellence
Key Topics include:
- Compliance Groundswell: What are the New Rules and Regulator Expectations?
- Global Dynamics of Risk: Can Technology Keep Pace?
- Benchmarking Best Practices: Upgrading Company Performance Culture
- What's Ahead: How Logistics and Distribution Science will Shape Tomorrow's Supply Chain
 Contact your sales rep for more information and to secure your sponsorship. |
 |
 //Cesca Therapeutics (Cordova, CA) announced that Kenneth L. Harris is stepping down as President of the company and from the Board of Directors in the U.S., as well as in the Indian subsidiaries. Mr. Harris will remain involved with the company as an independent advisor for up to 18 months.//Calithera Biosciences (South San Francisco, CA) appointed Dr. Sunil Agarwal, M.D., Chief Medical Officer and Senior Vice President at Ultragenyx Pharmaceutical, as an independent director.//BioCryst Pharmaceuticals (Research Triangle Park, NC) elected Sanj K.Patel to the company's Board of Directors.//Alder BioPharmaceuticals (Bothell, WA) appointed Paul R. Carter to its Board of Directors, effective immediately. Mr. Carter currently serves as Executive Vice President, Commercial Operations at Gilead Sciences. //Neothetics (San Diego, CA) named Jeffrey Nugent and Hani Zeini to its Board of Directors.//Global Blood Therapeutics (South San Francisco, CA) appointed Philip A. Pizzo, M.D., founding director of the Stanford Distinguished Careers Institute and former Dean of Stanford University School of Medicine, to its Board of Directors.// |
|
Pharmaceutical Executive E-Book – Coming October 2015: Changing Contours of Commercialization: Impact of US Health Reform on Patients, Payers and Providers
Key Topics include:
- Phase-in of the 2010 Affordable Care Act: Five stages of pain and plenty
- Pay for Performance and Shared Savings Programs – Implications for Pharma Marketers
- How ACO models are driving physician and provider decision-making
- Primer on policies and financial drivers impacting payer markets – MLR, MSSP, CMS etc.
 Contact your sales rep for more information and to secure your sponsorship. |
|
New tufts CSDD Research
Industry Adoption of eClinical Solutions and CDISC Standards
LIVE WEBCAST: Thursday, October 8, 2015 at 11:00 am ET
 Register for free
|
|
|
